The Role of SBRT in Oligometastatic Prostate Cancer: Where We Are and Where We Are Heading
Life · 26.03.2026 · 16 (4) · 550
DOI: 10.3390/life16040550 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Life, online erschienen am 26.03.2026. Verfasst von Macarena Teja und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, GenesisCare-Vithas La Milagrosa University Hospital, 28010 Madrid, Spain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Oligometastatic prostate cancer represents a distinct biological state between localized and widely metastatic disease, characterized by a limited number of lesions. Stereotactic body radiotherapy (SBRT) has emerged as a key metastasis-directed therapy (MDT), enabling precise ablation of metastatic lesions with minimal toxicity. Prospective clinical trials such as SABR-COMET, STOMP, ORIOLE, RADIOSA, and EXTEND have shown that SBRT delays disease progression, prolongs progression-free survival, and postpones the need for systemic therapy, while maintaining a favorable safety profile. Nevertheless, methodological limitations persist, including heterogeneity in defining oligometastatic disease, variability in dosing and fractionation, and the lack of predictive biomarkers. Ongoing phase III trials aim to validate the integration of SBRT with modern systemic therapies, including next-generation androgen receptor pathway inhibitors, to optimize clinical outcomes in hormone-sensitive and castration-resistant oligometastatic prostate cancer. This review summarizes current evidence, clinical applications, and future directions for SBRT in this patient population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, GenesisCare-Vithas La Milagrosa University Hospital, 28010 Madrid, Spain.
- Department of Radiation Oncology, GenesisCare-San Francisco de Asís University Hospital, 28002 Madrid, Spain.
- PhD Program in Medicine and Surgery, Escuela de Doctorado, Universidad Autónoma de Madrid, 28049 Madrid, Spain.
- Department of Radiation Oncology, Vithas Consuelo Hospital, GenesisCare, 46007 Valencia, Spain.
- Department of Radiation Oncology, La Fe Hospital, 46206 Valencia, Spain.
- Department of Radiation Oncology, Ramón y Cajal University Hospital, 28034 Madrid, Spain.
ORCID-Profile: Macarena Teja, Miguel Angel Berenguer Frances, Fernando López Campos, Nicolas Feltes Benítez, Andrea Puertas, Giulia Marvaso, Felipe Couñago
Zitieren
APA
Teja, M., Berenguer Frances, M. A., López Campos, F., Feltes Benítez, N., Stoica, A., Puertas, A., Marvaso, G., Murthy, V., & Couñago, F. (2026). The Role of SBRT in Oligometastatic Prostate Cancer: Where We Are and Where We Are Heading. Life, 16(4), 550. https://doi.org/10.3390/life16040550
Vancouver
Teja M, Berenguer Frances MA, López Campos F, Feltes Benítez N, Stoica A, Puertas A, et al. The Role of SBRT in Oligometastatic Prostate Cancer: Where We Are and Where We Are Heading. Life. 2026;16(4):550. doi:10.3390/life16040550
BibTeX
@article{Teja2026,
author = {Teja, Macarena and Berenguer Frances, Miguel Angel and López Campos, Fernando and Feltes Benítez, Nicolas and Stoica, Alexandra and Puertas, Andrea and Marvaso, Giulia and Murthy, Vedang and Couñago, Felipe},
title = {The Role of SBRT in Oligometastatic Prostate Cancer: Where We Are and Where We Are Heading},
journal = {Life},
year = {2026},
volume = {16},
number = {4},
pages = {550},
doi = {10.3390/life16040550}
}
EUVIMED